PDF(Pubmed)
Abstract：
BACKGROUND: Hepatectomy is the first choice for treating liver cancer. However, inflammatory factors, released in response to pain stimulation, may suppress perioperative immune function and affect the prognosis of patients undergoing hepatectomies.
OBJECTIVE: To determine the short-term efficacy of microwave ablation in the treatment of liver cancer and its effect on immune function.
METHODS: Clinical data from patients with liver cancer admitted to Suzhou Ninth People\'s Hospital from January 2020 to December 2023 were retrospectively analyzed. Thirty-five patients underwent laparoscopic hepatectomy for liver cancer (liver cancer resection group) and 35 patients underwent medical image-guided microwave ablation (liver cancer ablation group). The short-term efficacy, complications, liver function, and immune function indices before and after treatment were compared between the two groups.
RESULTS: One month after treatment, 19 patients experienced complete remission (CR), 8 patients experienced partial remission (PR), 6 patients experienced stable disease (SD), and 2 patients experienced disease progression (PD) in the liver cancer resection group. In the liver cancer ablation group, 21 patients experienced CR, 9 patients experienced PR, 3 patients experienced SD, and 2 patients experienced PD. No significant differences in efficacy and complications were detected between the liver cancer ablation and liver cancer resection groups (P > 0.05). After treatment, total bilirubin (41.24 ± 7.35 vs 49.18 ± 8.64 μmol/L, P < 0.001), alanine aminotransferase (30.85 ± 6.23 vs 42.32 ± 7.56 U/L, P < 0.001), CD4+ (43.95 ± 5.72 vs 35.27 ± 5.56, P < 0.001), CD8+ (20.38 ± 3.91 vs 22.75 ± 4.62, P < 0.001), and CD4+/CD8+ (2.16 ± 0.39 vs 1.55 ± 0.32, P < 0.001) were significantly different between the liver cancer ablation and liver cancer resection groups.
CONCLUSIONS: The short-term efficacy and safety of microwave ablation and laparoscopic surgery for the treatment of liver cancer are similar, but liver function recovers quickly after microwave ablation, and microwave ablation may enhance immune function.
OBJECTIVE: To determine the short-term efficacy of microwave ablation in the treatment of liver cancer and its effect on immune function.
METHODS: Clinical data from patients with liver cancer admitted to Suzhou Ninth People\'s Hospital from January 2020 to December 2023 were retrospectively analyzed. Thirty-five patients underwent laparoscopic hepatectomy for liver cancer (liver cancer resection group) and 35 patients underwent medical image-guided microwave ablation (liver cancer ablation group). The short-term efficacy, complications, liver function, and immune function indices before and after treatment were compared between the two groups.
RESULTS: One month after treatment, 19 patients experienced complete remission (CR), 8 patients experienced partial remission (PR), 6 patients experienced stable disease (SD), and 2 patients experienced disease progression (PD) in the liver cancer resection group. In the liver cancer ablation group, 21 patients experienced CR, 9 patients experienced PR, 3 patients experienced SD, and 2 patients experienced PD. No significant differences in efficacy and complications were detected between the liver cancer ablation and liver cancer resection groups (P > 0.05). After treatment, total bilirubin (41.24 ± 7.35 vs 49.18 ± 8.64 μmol/L, P < 0.001), alanine aminotransferase (30.85 ± 6.23 vs 42.32 ± 7.56 U/L, P < 0.001), CD4+ (43.95 ± 5.72 vs 35.27 ± 5.56, P < 0.001), CD8+ (20.38 ± 3.91 vs 22.75 ± 4.62, P < 0.001), and CD4+/CD8+ (2.16 ± 0.39 vs 1.55 ± 0.32, P < 0.001) were significantly different between the liver cancer ablation and liver cancer resection groups.
CONCLUSIONS: The short-term efficacy and safety of microwave ablation and laparoscopic surgery for the treatment of liver cancer are similar, but liver function recovers quickly after microwave ablation, and microwave ablation may enhance immune function.
摘要：
背景：肝切除术是治疗肝癌的首选方法。然而,炎症因子，响应疼痛刺激而释放，可能抑制围手术期免疫功能，影响肝切除术患者的预后。
目的：探讨微波消融治疗肝癌的近期疗效及对免疫功能的影响。
方法：回顾性分析2020年1月至2023年12月苏州市第九人民医院收治的肝癌患者的临床资料。35例患者行腹腔镜肝癌切除术(肝癌切除组),35例患者行医学图像引导微波消融(肝癌消融组)。短期疗效，并发症,肝功能,比较两组患者治疗前后的免疫功能指标。
结果：治疗后一个月，19例患者完全缓解（CR），8例患者部分缓解（PR），6例患者经历了稳定的疾病（SD），肝癌切除组2例患者出现疾病进展(PD)。在肝癌消融组中，21例患者出现CR，9例患者经历PR，3名患者经历了SD，2例患者发生PD。肝癌消融组与肝癌切除组的疗效及并发症比较差异无统计学意义(P>0.05)。治疗后,总胆红素（41.24±7.35vs49.18±8.64μmol/L，P<0.001)，丙氨酸转氨酶（30.85±6.23vs42.32±7.56U/L，P<0.001)，CD4+(43.95±5.72vs35.27±5.56,P<0.001),CD8+(20.38±3.91vs22.75±4.62,P<0.001),CD4+/CD8+(2.16±0.39vs1.55±0.32,P<0.001)在肝癌消融组和肝癌切除组之间差异有统计学意义。
结论：微波消融和腹腔镜手术治疗肝癌的短期疗效和安全性相似，但是微波消融后肝功能很快恢复，微波消融可增强免疫功能。
目的：探讨微波消融治疗肝癌的近期疗效及对免疫功能的影响。
方法：回顾性分析2020年1月至2023年12月苏州市第九人民医院收治的肝癌患者的临床资料。35例患者行腹腔镜肝癌切除术(肝癌切除组),35例患者行医学图像引导微波消融(肝癌消融组)。短期疗效，并发症,肝功能,比较两组患者治疗前后的免疫功能指标。
结果：治疗后一个月，19例患者完全缓解（CR），8例患者部分缓解（PR），6例患者经历了稳定的疾病（SD），肝癌切除组2例患者出现疾病进展(PD)。在肝癌消融组中，21例患者出现CR，9例患者经历PR，3名患者经历了SD，2例患者发生PD。肝癌消融组与肝癌切除组的疗效及并发症比较差异无统计学意义(P>0.05)。治疗后,总胆红素（41.24±7.35vs49.18±8.64μmol/L，P<0.001)，丙氨酸转氨酶（30.85±6.23vs42.32±7.56U/L，P<0.001)，CD4+(43.95±5.72vs35.27±5.56,P<0.001),CD8+(20.38±3.91vs22.75±4.62,P<0.001),CD4+/CD8+(2.16±0.39vs1.55±0.32,P<0.001)在肝癌消融组和肝癌切除组之间差异有统计学意义。
结论：微波消融和腹腔镜手术治疗肝癌的短期疗效和安全性相似，但是微波消融后肝功能很快恢复，微波消融可增强免疫功能。
